Top

Published in:

Open Access 01-02-2008 | Original

The effect of sodium valproate on chronic daily headache and its subgroups

Authors: Vedat Ali Yurekli, Galip Akhan, Suleyman Kutluhan, Ertugrul Uzar, Hasan Rifat Koyuncuoglu, Fatih Gultekin

Published in: The Journal of Headache and Pain | Issue 1/2008

Abstract

The objective of the study was to assess the efficacy and tolerability of sodium valproate (VPA) on chronic daily headache (CDH) in a prospective, double-blind, randomized, placebo-controlled trial. Seventy patients were included in the study. Twenty-nine had chronic migraine (CM) and 41 had chronic tension-type headache (CTTH). VPA and placebo were applied for 3 months to 40 and 30 patients, respectively. Visual analog scale (VAS) and pain frequency (PF) were used for evaluation. VPA decreased the maximum pain VAS levels (MaxVAS) and PF at the end of the study (P = 0.028 and P = 0.000, respectively), but did not change general pain VAS (GnVAS) levels (P = 0.198). In CM patients, the decreases in MaxVAS, GnVAS and PF parameters were more in VPA treated patients (P = 0.006, P = 0.03, and P = 0.000, respectively). VPA treatment caused more reduction in PF than placebo in the CTTH subgroup (P = 0.000). VPA is effective in the prophylactic treatment of CDH by reducing MaxVAS levels and PF. It was more effective in CM than in CTTH.

Schwartz TH, Karpitskiy VV, Sohn RS (2002) Intravenous valproate sodium in the treatment of daily headache. Headache 42(6):519–522, 12167141, 10.1046/j.1526-4610.2002.02127.xCrossRefPubMed

Silberstein SD, Lipton RB, Sliwinski M (1996) Classification of daily and near-daily headache: a field study of revised IHS criteria. Neurology 47:871–875, 8857711, 1:STN:280:DyaK2s%2FhtVKkug%3D%3DCrossRefPubMed

Freitag FG, Diamond S, Diamond ML, Urban GJ (2001) Divalproex in the long-term treatment of chronic daily headache. Headache 41:271–278, 11264687, 10.1046/j.1526-4610.2001.111006271.x, 1:STN:280:DC%2BD3M7ms1ehtg%3D%3DCrossRefPubMed

Sorensen KV (1988) Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 78:346–348, 3146862, 1:STN:280:DyaL1M7jtFKjtQ%3D%3D, 10.1111/j.1600-0404.1988.tb03667.xCrossRefPubMed

Hering R, Kuritzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12(2):81–84, 1576648, 10.1046/j.1468-2982.1992.1202081.x, 1:STN:280:DyaK383kvVOjtg%3D%3DCrossRefPubMed

Hering R, Kuritzky A (1989) Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 9:195–198, 2507161, 10.1046/j.1468-2982.1989.0903195.x, 1:STN:280:DyaK3c%2FgtlWqug%3D%3DCrossRefPubMed

Jensen R, Brinck T, Olesen J (1994) Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 44(4):647–651, 8164818, 1:STN:280:DyaK2c3hslyqsg%3D%3DCrossRefPubMed

Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K; Depakote ER Migraine Study Group (2002) A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 11(58):1652–1659CrossRef

Taylor K, Goldstein J (1996) High-dose versus low-dose valproic acid as a prophylactic medication. Headache 36(8):514–515, 8824009, 10.1046/j.1526-4610.1996.3608514.x, 1:STN:280:DyaK28vitFensg%3D%3DCrossRefPubMed

10.

Klapper J (1997) Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17:103–108, 9137847, 10.1046/j.1468-2982.1997.1702103.x, 1:STN:280:DyaK2s3otlOluw%3D%3DCrossRefPubMed

11.

Hering R, Kuritzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12:81–84, 1576648, 10.1046/j.1468-2982.1992.1202081.x, 1:STN:280:DyaK383kvVOjtg%3D%3DCrossRefPubMed

12.

Kaniecki RG (1997) A comparison of divalproex with propanolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 54:1141–1145, 9311358, 1:STN:280:DyaK2svlslGnuw%3D%3DCrossRefPubMed

13.

Jensen R, Brinck T, Olesen J (1994) Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo controlled crossover study. Neurology 44:647–651, 8164818, 1:STN:280:DyaK2c3hslyqsg%3D%3DCrossRefPubMed

14.

Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group (2004) Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61:490–495, 15096395, 10.1001/archneur.61.4.490CrossRefPubMed

15.

Brandes JL, Saper JR, Diamond M, et al MIGR-002 Study Group (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291:965–973

16.

Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, Neto W, Vijapurkar U, Doyle A, Jacobs D, The MIGR-003 Study Group (2004) Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 251:943–950, 15316798, 10.1007/s00415-004-0464-6, 1:CAS:528:DC%2BD2cXosVSrtLc%3DPubMed

17.

Mathew NT, Rapoport A, Saper J et al (2001) Efficacy of gabapentin in migraine prophylaxis. Headache 41:119–128, 11251695, 10.1046/j.1526-4610.2001.111006119.x, 1:STN:280:DC%2BD3MzmvVKktw%3D%3DCrossRefPubMed

18.

Pascual J, Lainez MJ, Dodick D, Hering-Hanit R (2007) Antiepileptic drugs for the treatment of chronic and episodic cluster headache. Headache 47(1):81–89, 17355498, 10.1111/j.1526-4610.2007.00653.xCrossRefPubMed

19.

Mathew NT (2006) The prophylactic treatment of chronic daily headache. Headache 46(10):1552–1564, 17115988, 10.1111/j.1526-4610.2006.00621.xCrossRefPubMed

20.

Silberstein SD (2005) Chronic daily headache. JAOA 105(4 Suppl 2):23S–29S, 15928350PubMed

21.

Mathew NT, Ali S (1991) Valproate in the treatment of persistent chronic daily headache. An open label study. Headache 31(2):71–74, 2030076, 10.1111/j.1526-4610.1991.hed3102071.x, 1:STN:280:DyaK3M3jtFCjsA%3D%3DCrossRefPubMed

22.

Rothrock JF (1999) Management of chronic daily headache utilizing a uniform treatment pathway. Headache 39:650–653, 11279960, 10.1046/j.1526-4610.1999.3909650.x, 1:STN:280:DC%2BD3M7ovFWmsw%3D%3DCrossRefPubMed

23.

Vijayan N, Spillane T (1995) Valproic acid treatment of chronic daily headache. Headache 35:540–543, 8530278, 10.1111/j.1526-4610.1995.hed3509540.x, 1:STN:280:DyaK28%2FosVCrtg%3D%3DCrossRefPubMed

24.

Lenaerts M, Bastings E, Sianard J, Schoenen J (1996) Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels. Acta Neurol Belg 96(2):126–129, 8711985, 1:STN:280:DyaK28zjslCjsg%3D%3DPubMed

25.

Rothrock JF, Mendizabal JE (2000) An analysis of the “carry-over effect” following successful short-term treatment of transformed migraine with divalproex sodium. Headache 40(1):17–19, 10759897, 10.1046/j.1526-4610.2000.00002.x, 1:STN:280:DC%2BD3c3itlemtg%3D%3DCrossRefPubMed

Title: The effect of sodium valproate on chronic daily headache and its subgroups
Authors: Vedat Ali Yurekli
Galip Akhan
Suleyman Kutluhan
Ertugrul Uzar
Hasan Rifat Koyuncuoglu
Fatih Gultekin
Publication date: 01-02-2008
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2008
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1007/s10194-008-0002-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The effect of sodium valproate on chronic daily headache and its subgroups

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

More lessons for the treatment of chronic daily headache

Pharmacogenomics and migraine: possible implications

Thoughts on the past year of Journal of Headache and Pain

Erratum to: Thoughts on the past year of Journal of Headache and Pain

Sinusitis in children and adolescents with chronic or recurrent headache: a case–control study

Performances in cerebellar and neuromuscular transmission tests are correlated in migraine with aura